Presentation title : Subretinal gene therapy laru-zova for X-linked retinitis pigmentosa (XLRP): Phase 2 DAWN trial, preliminary month 9+ results Date : Thursday, September 4, 2025 Presenter : Rajiv ...

WILMINGTON, DE, UNITED STATES, August 21, 2025 /EINPresswire.com/ -- The global pigments market is witnessing significant ...

Men and women may be affected differently by retinitis pigmentosa, a disease that causes blindness over time. That's ...

ADX-2191 is a preservative-free intravitreal formulation of methotrexate designed to treat various rare retinal diseases such as retinitis pigmentosa.

Aldeyra Therapeutics received FDA fast track designation for ADX-2191 for the treatment of retinitis pigmentosa, according to ...

Analysts have recently evaluated Regenxbio and provided 12-month price targets. The average target is $38.4, accompanied by a high estimate of $52.00 and a low estimate of $17.00. Highlighting a 8.13% ...

Aldeyra Therapeutics ( ($ALDX) ) has shared an update. On August 19, 2025, Aldeyra Therapeutics announced that the FDA granted Fast Track ...

Aldeyra (ALDX) announced that the FDA has granted fast track designation for ADX-2191 for the treatment of retinitis pigmentosa. There is ...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal ...

“Where the retina cells have been regenerated, the light receptors are rebuilt, which allow the patient to see again within a ...

Cyte initiates patient dosing in a new trial for famzeretcel, aiming to transform treatment options for retinitis pigmentosa.

In this Healio Video Perspective from the Retina World Congress, Huma Qamar, MD, MPH, of Ocugen, overviews programs for ...